These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29972862)

  • 1. Major Changes of von Willebrand Factor Multimer Distribution in Cirrhotic Patients with Stable Disease or Acute Decompensation.
    Palyu E; Harsfalvi J; Tornai T; Papp M; Udvardy M; Szekeres-Csiki K; Pataki L; Vanhoorelbeke K; Feys HB; Deckmyn H; Tornai I
    Thromb Haemost; 2018 Aug; 118(8):1397-1408. PubMed ID: 29972862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome.
    Hugenholtz GC; Adelmeijer J; Meijers JC; Porte RJ; Stravitz RT; Lisman T
    Hepatology; 2013 Aug; 58(2):752-61. PubMed ID: 23468040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ADAMTS13-von Willebrand factor axis in COVID-19 patients.
    Mancini I; Baronciani L; Artoni A; Colpani P; Biganzoli M; Cozzi G; Novembrino C; Boscolo Anzoletti M; De Zan V; Pagliari MT; Gualtierotti R; Aliberti S; Panigada M; Grasselli G; Blasi F; Peyvandi F
    J Thromb Haemost; 2021 Feb; 19(2):513-521. PubMed ID: 33230904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
    Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
    World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity.
    Lisman T; Bongers TN; Adelmeijer J; Janssen HL; de Maat MP; de Groot PG; Leebeek FW
    Hepatology; 2006 Jul; 44(1):53-61. PubMed ID: 16799972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered von Willebrand Factor and ADAMTS13 Levels in Children With Cirrhosis and Extrahepatic Portal Hypertension.
    Islek A; Ilhan D; Ozturk N; Guven B; Sag E
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e951-e956. PubMed ID: 33369998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W.
    Pruss CM; Golder M; Bryant A; Hegadorn C; Haberichter S; Lillicrap D
    J Thromb Haemost; 2012 May; 10(5):940-50. PubMed ID: 22372972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis.
    Reuken PA; Kussmann A; Kiehntopf M; Budde U; Stallmach A; Claus RA; Bruns T
    Liver Int; 2015 Jan; 35(1):37-45. PubMed ID: 25113276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis.
    Feys HB; Canciani MT; Peyvandi F; Deckmyn H; Vanhoorelbeke K; Mannucci PM
    Br J Haematol; 2007 Aug; 138(4):534-40. PubMed ID: 17608762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VWF/ADAMTS13 Imbalance, But Not Global Coagulation or Fibrinolysis, Is Associated With Outcome and Bleeding in Acute Liver Failure.
    Driever EG; Stravitz RT; Zhang J; Adelmeijer J; Durkalski V; Lee WM; Lisman T
    Hepatology; 2021 May; 73(5):1882-1891. PubMed ID: 32767567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balance between von Willebrand factor and ADAMTS13 following major partial hepatectomy.
    Groeneveld DJ; Alkozai EM; Adelmeijer J; Porte RJ; Lisman T
    Br J Surg; 2016 May; 103(6):735-743. PubMed ID: 27005894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of HeartWare ventricular assist device on the von Willebrand factor: results of an academic Belgian center.
    Esmaeilzadeh F; Wauters A; Wijns W; Argacha JF; van de Borne P
    BMC Cardiovasc Disord; 2016 Aug; 16(1):155. PubMed ID: 27485105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
    Budde U; Schneppenheim R
    Hamostaseologie; 2014; 34(3):215-25. PubMed ID: 25010251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of active Von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: a multicenter and multiethnic study.
    Rutten B; Maseri A; Cianflone D; Laricchia A; Cristell NA; Durante A; Spartera M; Ancona F; Limite L; Hu D; Li H; Uren NG; de Groot PG; Mannucci PM; Roest M
    Eur Heart J Acute Cardiovasc Care; 2015 Feb; 4(1):64-74. PubMed ID: 24833640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of von Willebrand factor multimer size and implications for disease.
    Pimanda J; Hogg P
    Blood Rev; 2002 Sep; 16(3):185-92. PubMed ID: 12163004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation.
    Reiter RA; Varadi K; Turecek PL; Jilma B; Knöbl P
    Thromb Haemost; 2005 Mar; 93(3):554-8. PubMed ID: 15735809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation.
    Horii M; Uemura S; Uemura M; Matsumoto M; Ishizashi H; Imagawa K; Iwama H; Takeda Y; Kawata H; Nakajima T; Fujimura Y; Saito Y
    Heart Vessels; 2008 Sep; 23(5):301-7. PubMed ID: 18810578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance.
    Philippe A; Gendron N; Bory O; Beauvais A; Mirault T; Planquette B; Sanchez O; Diehl JL; Chocron R; Smadja DM
    Angiogenesis; 2021 Aug; 24(3):407-411. PubMed ID: 33974165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma ADAMTS13, von Willebrand Factor (VWF), and VWF Propeptide Profiles in Patients With Connective Tissue Diseases and Antiphospholipid Syndrome.
    Habe K; Wada H; Matsumoto T; Ohishi K; Ikejiri M; Tsuda K; Kondo M; Kamimoto Y; Ikeda T; Katayama N; Mizutani H
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):622-630. PubMed ID: 26759371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure.
    De Filippis V; Lancellotti S; Maset F; Spolaore B; Pozzi N; Gambaro G; Oggianu L; Calò LA; De Cristofaro R
    Biochem J; 2012 Mar; 442(2):423-32. PubMed ID: 22091998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.